Related Experiment Video
Updated: Aug 22, 2025
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
CXCR4 knockout induces neuropathological changes in the MPTP-lesioned model of Parkinson's disease
Jianjun Ma1, Linrui Dong2, Qingqing Chang2
1Department of Neurology, Henan Provincial People's Hospital, Zhengzhou 450003, PR China; Department of Neurology, Zhengzhou University People's Hospital, Zhengzhou 450003, PR China; Department of Neurology, Henan University People's Hospital, Zhengzhou 450003, PR China.
Abstract:
C-X-C chemokine receptor type 4 (CXCR4) is highly expressed in Parkinson's disease (PD) mice's brains and is related to astrocyte signaling and microglial activation. This makes CXCR4 related to neuroinflammation and also makes CXCR4 considered to be the PD development mechanism and possible therapeutic targets. Therefore, it is worth studying the effect of CXCR4 on neuropathological changes and its potential therapeutic value for PD. This study aimed to investigate the effect of CXCR4 knockout on neuropathological changes in the mouse model of PD and its mechanism. In this study, CXCR4-WT and CXCR4+/- C57BL mice were used to make Parkinson's model. Behavioral experiments, dopaminergic neuron markers, neuroinflammation, and blood-brain barrier damage were detected to verify the effect of CXCR4 knockout on neuropathological changes. CXCR4 knockout improved the behavioral results and tyrosine hydroxylase (TH) expression of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned mice. In the substantia nigra (SN) area of the brain of PD mouse model, the number of Iba1-positive (p = 0.0004) and GFAP-positive cells (p = 0.0349) was significantly lower in CXCR4 knockout group than CXCR4-WT group. CXCR4 knockout reduced MPTP-induced infiltration of peripheral immune cells and the expression of pro-inflammatory cytokines. CXCR4 knockout also protected blood-brain barrier (BBB) from MPTP-induced damage. In conclusion, CXCR4 knockout inhibits the degeneration of dopamine neurons, microglial and astrocyte activation, neuroinflammation, and BBB damages in the MPTP-lesioned PD mice.
Insights
Targeting C-X-C chemokine receptor type 4 (CXCR4) may offer a new Parkinson's disease (PD) therapy. CXCR4 knockout in mice reduced neuroinflammation, protected dopamine neurons, and improved PD symptoms.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- C-X-C chemokine receptor type 4 (CXCR4) is upregulated in Parkinson's disease (PD) brains.
- CXCR4 is implicated in astrocyte signaling, microglial activation, and neuroinflammation, suggesting its role in PD pathogenesis.
- CXCR4 represents a potential therapeutic target for PD.
Purpose of the Study:
- To investigate the therapeutic potential of CXCR4 knockout in a mouse model of PD.
- To elucidate the mechanisms by which CXCR4 influences neuropathological changes in PD.
Main Methods:
- Utilized CXCR4-WT and CXCR4+/- C57BL mice to establish a PD model using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
- Assessed behavioral outcomes, dopaminergic neuron markers (tyrosine hydroxylase), neuroinflammation (Iba1, GFAP), and blood-brain barrier (BBB) integrity.
Main Results:
- CXCR4 knockout significantly improved behavioral deficits and enhanced tyrosine hydroxylase expression in MPTP-lesioned mice.
- Reduced microglial (Iba1) and astrocyte (GFAP) activation in the substantia nigra of CXCR4 knockout PD mice.
- CXCR4 knockout mitigated MPTP-induced peripheral immune cell infiltration, pro-inflammatory cytokine expression, and BBB damage.
Conclusions:
- CXCR4 knockout confers neuroprotection in a PD mouse model.
- Inhibiting CXCR4 ameliorates dopamine neuron degeneration, neuroinflammation, and BBB disruption in PD.
